Am J Transplant, Volume 20, Suppl 3 Archives - Page 126 of 223 - ATC Abstracts

2020 American Transplant Congress
CD4+ T-Cells Express High Levels of Messenger RNA Coding for Heparanase in Cultures with Matrigel
N. Chai, G. Wu, I. Kim, S. Jordan, A. Klein, T. Brennan
Cedars-Sinai Med Ctr, Los Angeles, CA
*Purpose: Heparanase (Hpse) is the sole heparan sulfate (HS) degrading enzyme regulating multiple biological activities that enhance immune cell migration, blood vessel growth and cell…
2020 American Transplant Congress
Everolimus-Treatment Inhibits the Transition of the Immature Subsets of Liver Natural Killer Cells to Mature State and Enhances Anti-Tumor Activity
Y. Tanaka, J. Saparbay, H. Ohdan
Gastreenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: The immunosuppressive regimen currently used after organ transplantation efficiently reduces the adaptive immune components. During suppressed adaptive immunity, the innate immune cells may play…
2020 American Transplant Congress
HLA Molecular Mismatch Analysis in Recipients of Kidney Plus Hematopoietic Stem/Facilitating Cell Transplant Tolerance Induction Protocol
C. Garcia-Sanchez¹, V. Kosmoliaptsis², H. Copley², J. Leventhal¹, S. Ildstad³
¹NU, Chicago, IL, ²Cambridge, Cambridge, United Kingdom, ³U of Louisville, Lousville, KY
*Purpose: To evaluate the potential role of HLA molecular mismatch (MM) analysis in predicting outcomes in a cohort of HLA-mismatched, related and unrelated recipients of…
2020 American Transplant Congress
Belatacept Monthly Therapy: Transplant Recipients’ Experience
S. N. Little¹, É. N. Arsenault Knudsen², D. A. Mandelbrot¹
¹Transplant, University of Wisconsin Hospital and Clinics, Madison, WI, ²University of Wisconsin Hospital and Clinics, Madison, WI
*Purpose: While graft and patient outcomes with belatacept have been relatively well documented, the decision to use belatacept for kidney transplant recipients rests in part…
2020 American Transplant Congress
A Multicenter, Randomized, Controlled Trial to Steer Immunosuppressive Therapy by Virus-Specific T Cells after Pediatric Kidney Transplantation (IVIST-Trial)
T. Ahlenstiel-Grunow¹, A. Großhennig¹, R. Schild², J. Oh², C. Taylan³, L. Weber³, H. Staude⁴, M. Verboom¹, C. Schröder¹, R. Sabau¹, A. Koch¹, X. Liu¹, L. Pape¹
¹Hannover Medical School, Hannover, Germany, ²University Hospital Hamburg-Eppendorf, Hamburg, Germany, ³University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany, ⁴University Hospital of Rostock, Rostock, Germany
*Purpose: Pharmakokinetic monitoring of immunosuppressants alone is insufficient to estimate the individual intensity of immunosuppression after kidney transplantation (Tx). Virus-specific T cells (Tvis) correlate with…
2020 American Transplant Congress
The FcγRIIIa-158 VV Genotype Increased the Risk of Post-Transplant Lymphoproliferative Disorder in T-Cell Depleted Kidney Transplant Recipients
P. Gatault¹, L. Lajoie¹, J. Stojanova², P. Marquet², G. Thibault¹
¹CHU Tours, Tours, France, ²CHU Limoges, Limoges, France
*Purpose: Post-transplantation lymphoproliferative disorder (PTLD) is a severe complication in organ transplant recipients. The use of T lymphocyte-depleting antibodies (TLDAb), especially rabbit TLDAb contributes to…
2020 American Transplant Congress
Kidney Paired Donation Outcomes among High PRA Recipients
A. Thomas¹, A. Shaffer², M. Henderson², D. Segev²
¹University of North Carolina, Chapel Hill, NC, ²Johns Hopkins, Baltimore, MD
*Purpose: Kidney paired donation (KPD) accounts for an increasing amount of living donor transplants in the US. Previous studies have shown equivalent outcomes between transplants…
2020 American Transplant Congress
What Are the Peri-Operative and Longterm Outcomes of Utilizing Donation after Circulatory Death Livers with Macrosteatosis? A Multicenter Analysis
K. Croome¹, A. Mathur², S. Mao¹, B. Aqel³, P. Senada¹, J. Piatt¹, J. Heimbach⁴, A. Moss³, C. Rosen⁴, C. Taner¹
¹Mayo Clinic Jacksonville, Jacksonville, FL, ²Mayo Clinic Arizona, Scotsdale, AZ, ³Mayo Clinic Arizona, Scottsdale, AZ, ⁴Mayo Clinic Rochester, Rochester, MN
*Purpose: Given the potentially additive risk from using donor livers that are both steatotic and from a donation after circulatory death(DCD) donor, there is a…
2020 American Transplant Congress
Can Biliary Internal Stents Reduce Biliary Complications in Adult Liver Transplantation?
Y. Kwon¹, Y. S. Genyk¹, Y. Yoon²
¹Division of Hepatobiliary, Pancreas, and Abdominal Organ Transplant, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, ²Division of Hepatobiliary, Pancreas, and Abdominal Organ Transplant, Department of Surgery, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea, Republic of
*Purpose: Biliary complications remain a consistent cause of morbidity and mortality in liver transplant (LT) recipients and there is controversy as to whether the use…
2020 American Transplant Congress
Multiplicity of Non-HLA Targets for Antibodies Developed in Association with Ventricular Assist Device Implantation
M. Askar, D. Bhakta, H. Zafar, A. Alam, L. Pittmon, S. Kang, L. Klingman, J. Felius, S. M. Joseph, D. Wencker, D. M. Meyer, S. A. Hall
Baylor University Medical Center and Baylor Scott & White Research Institute, Dallas, TX
*Purpose: Multiple non-HLA antibodies have been implicated in poor outcomes after heart transplantation. Development of HLA and Non-HLA antibodies have been reported in association with…